Cookies help us deliver our services. By using our services, you agree to our use of cookies. More information

Difference between revisions of "Template:SUIT-019"

From Bioblast
Line 11: Line 11:
| [[Fatty acid oxidation pathway control state| F(N)]]
| [[Fatty acid oxidation pathway control state| F(N)]]
| CETF
| CETF
| PalM<sub>''L''</sub>: Palmitoylcarnitine & malate, F-LEAK respiration, F<sub>''L''</sub>
| 1PalM


{{Template:SUIT F}} {{Template:SUIT L(n)}}
*{{Template:SUIT F}}
*{{Template:SUIT L(n)}}


|-
|-
Line 22: Line 23:
| 1PalM;2D
| 1PalM;2D


{{Template:SUIT F}} {{Template:SUIT OXPHOS}}
*{{Template:SUIT F}}
*{{Template:SUIT OXPHOS}}
 
|-
| 2c
| [[PalM]]<sub>''P''</sub>
| [[Fatty acid oxidation pathway control state| F(N)]]
| CETF
| 1PalM;2D;2c
 
*{{Template:SUIT c}}
*{{Template:SUIT F}}
*{{Template:SUIT OXPHOS}}  


|-
|-
Line 29: Line 42:
| [[Fatty acid oxidation pathway control state| F(N)]]
| [[Fatty acid oxidation pathway control state| F(N)]]
| CETF
| CETF
| 1PalM;2D;3Oct
| 1PalM;2D;2c;3Oct


{{Template:SUIT F}} {{Template:SUIT OXPHOS}}  
*{{Template:SUIT F}}
*{{Template:SUIT OXPHOS}}  


|-
|-
Line 38: Line 52:
| [[FN]]
| [[FN]]
| CETF&I
| CETF&I
| 1PalM;2D;3Oct;4P
| 1PalM;2D;2c;3Oct;4P


{{Template:SUIT F}} & {{Template:SUIT N}} {{Template:SUIT FN}} {{Template:SUIT OXPHOS}}
*{{Template:SUIT F}} & {{Template:SUIT N}}
*{{Template:SUIT FN}}
*{{Template:SUIT OXPHOS}}


|-
|-
Line 47: Line 63:
| [[FN]]
| [[FN]]
| CETF&I
| CETF&I
| 1PalM;2D;3Oct;4P;5G
| 1PalM;2D;2c;3Oct;4P;5G


{{Template:SUIT F}} & {{Template:SUIT N}} {{Template:SUIT FN}} {{Template:SUIT OXPHOS}}
*{{Template:SUIT F}} & {{Template:SUIT N}}
*{{Template:SUIT FN}}
*{{Template:SUIT OXPHOS}}


|-
|-
Line 56: Line 74:
| [[FN]]
| [[FN]]
| CETF&CI&II
| CETF&CI&II
| 1PalM;2D;3Oct;4P;5G;6U
| 1PalM;2D;2c;3Oct;4P;5G;6U


{{Template:SUIT F}} & {{Template:SUIT N}} {{Template:SUIT FN}} {{Template:SUIT U*}} {{Template:SUIT ET}}
*{{Template:SUIT F}} & {{Template:SUIT N}}
*{{Template:SUIT FN}}
*{{Template:SUIT U*}}
*{{Template:SUIT ET}}


|-
|-
Line 65: Line 86:
| [[FNS]]
| [[FNS]]
| CI&CII
| CI&CII
| 1PalM;2D;3Oct;4P;5G;6U;7S
| 1PalM;2D;2c;3Oct;4P;5G;6U;7S


{{Template:SUIT F}} & {{Template:SUIT N}} {{Template:SUIT FN}} {{Template:SUIT S}} {{Template:SUIT ET}}
*{{Template:SUIT F}} & {{Template:SUIT N}}
*{{Template:SUIT FN}}
*{{Template:SUIT S}}
*{{Template:SUIT ET}}


|-
|-
Line 74: Line 98:
| [[S]]
| [[S]]
| CII
| CII
| 1PalM;2D;3Oct;4P;5G;6U;7S
| 1PalM;2D;2c;3Oct;4P;5G;6U;7S;8Rot


{{Template:SUIT Rot}} {{Template:SUIT S}} {{Template:SUIT ET}}
*{{Template:SUIT Rot}}
|}
*{{Template:SUIT S}}
*{{Template:SUIT ET}}
 
|-
| 9Ama
| ROX
|
|  
| 1PalM;2D;2c;3Oct;4P;5G;6U;7S;8Rot;9Ama


*{{Template:SUIT Ama}}


|}


{{Template:SUIT CIV}}
{{Template:SUIT CIV}}
{{Template:Keywords in SUIT protocols}}
{{Template:Keywords in SUIT protocols}}

Revision as of 15:29, 28 January 2019

MitoPedia: SUIT

Steps and respiratory states

1PalM;2D;3Oct;4P;5G;6U;7S;8Rot-.png

Step State Pathway Q-junction Comment - Events (E) and Marks (M)
1PalM PalML F(N) CETF 1PalM
  • Respiratory stimulation of the FAO-pathway, F, by fatty acid, FA, in the presence of malate, M. Malate is a type N substrate (N), required for the F-pathway. The FA concentration has to be optimized to saturate the F-pathway, without inhibiting or uncoupling respiration.
  • Non-phosphorylating resting state (LEAK state); LEAK respiration L(n) in the absence of ADP, ATP, AMP (no adenylates).
2D PalMP F(N) CETF 1PalM;2D
  • Respiratory stimulation of the FAO-pathway, F, by fatty acid, FA, in the presence of malate, M. Malate is a type N substrate (N), required for the F-pathway. The FA concentration has to be optimized to saturate the F-pathway, without inhibiting or uncoupling respiration.
  • OXPHOS capacity P (with saturating [ADP]), active OXPHOS state.
2c PalMP F(N) CETF 1PalM;2D;2c
  • Addition of cytochrome c yields a test for integrity of the mtOM (cytochrome c control efficiency). Stimulation by added cytochrome c would indicate an injury of the mtOM and limitation of respiration in the preceding state without added c due to loss of cytochrome c. Typically, cytochrome c is added immediately after the earliest ADP-activation step (OXPHOS capacity P with saturating [ADP]).
  • Respiratory stimulation of the FAO-pathway, F, by fatty acid, FA, in the presence of malate, M. Malate is a type N substrate (N), required for the F-pathway. The FA concentration has to be optimized to saturate the F-pathway, without inhibiting or uncoupling respiration.
  • OXPHOS capacity P (with saturating [ADP]), active OXPHOS state.
3Oct PalOctMP F(N) CETF 1PalM;2D;2c;3Oct
  • Respiratory stimulation of the FAO-pathway, F, by fatty acid, FA, in the presence of malate, M. Malate is a type N substrate (N), required for the F-pathway. The FA concentration has to be optimized to saturate the F-pathway, without inhibiting or uncoupling respiration.
  • OXPHOS capacity P (with saturating [ADP]), active OXPHOS state.
4P PalOctPMP FN CETF&I 1PalM;2D;2c;3Oct;4P
  • Respiratory stimulation of the FAO-pathway, F, by fatty acid, FA, in the presence of malate, M. Malate is a type N substrate (N), required for the F-pathway. The FA concentration has to be optimized to saturate the F-pathway, without inhibiting or uncoupling respiration. & NADH-linked substrates (type N-pathway to Q).
  • Respiratory stimulation by simultaneous action of the F-pathway and N-pathway with convergent electron flow in the FN-pathway for evaluation of an additive or inhibitory effect of F.
  • OXPHOS capacity P (with saturating [ADP]), active OXPHOS state.
5G PalOctPGMP FN CETF&I 1PalM;2D;2c;3Oct;4P;5G
  • Respiratory stimulation of the FAO-pathway, F, by fatty acid, FA, in the presence of malate, M. Malate is a type N substrate (N), required for the F-pathway. The FA concentration has to be optimized to saturate the F-pathway, without inhibiting or uncoupling respiration. & NADH-linked substrates (type N-pathway to Q).
  • Respiratory stimulation by simultaneous action of the F-pathway and N-pathway with convergent electron flow in the FN-pathway for evaluation of an additive or inhibitory effect of F.
  • OXPHOS capacity P (with saturating [ADP]), active OXPHOS state.
6U PalOctPGME FN CETF&CI&II 1PalM;2D;2c;3Oct;4P;5G;6U
7S PalOctPGMSE FNS CI&CII 1PalM;2D;2c;3Oct;4P;5G;6U;7S
8Rot SE S CII 1PalM;2D;2c;3Oct;4P;5G;6U;7S;8Rot
9Ama ROX 1PalM;2D;2c;3Oct;4P;5G;6U;7S;8Rot;9Ama
  • Rox is the residual oxygen consumption in the ROX state, due to oxidative side reactions, estimated after addition of antimycin A (inhibitor of CIII). Rox is subtracted from oxygen flux as a baseline for all respiratory states, to obtain mitochondrial respiration (mt).
Step Respiratory state Pathway control ET-Complex Comment
## AsTm AsTmE CIV CIV
## Azd CHB


Questions.jpg


Click to expand or collaps